0001437749-24-007278.txt : 20240311 0001437749-24-007278.hdr.sgml : 20240311 20240311091042 ACCESSION NUMBER: 0001437749-24-007278 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240308 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pulse Biosciences, Inc. CENTRAL INDEX KEY: 0001625101 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 465696597 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37744 FILM NUMBER: 24736735 BUSINESS ADDRESS: STREET 1: 3957 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 510-906-4600 MAIL ADDRESS: STREET 1: 3957 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 FORMER COMPANY: FORMER CONFORMED NAME: Electroblate, Inc. DATE OF NAME CHANGE: 20141113 8-K 1 plse20240227_8k.htm FORM 8-K plse20240227_8k.htm
false 0001625101 0001625101 2024-03-08 2024-03-08
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): March 8, 2024
 
Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
     
Delaware
001-37744
46-5696597
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
3957 Point Eden Way 
Hayward, California 94545
(Address of Principal Executive Offices) (Zip Code)
 
510-906-4600
(Registrant’s Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share
PLSE
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 8.01
Other Events.
 
On March 8, 2024, Pulse Biosciences, Inc. (the “Company”) issued a press release announcing the FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System.  A copy of the Company’s press release is attached as Exhibit 99.1.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit
Number
Description
   
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
PULSE BIOSCIENCES, INC.
  
     
     
Date: March 11, 2024
By:
/s/ Kevin P. Danahy
  
   
Kevin P. Danahy
  
   
President and Chief Executive Officer
(Principal Executive and Principal Financial Officer)
  
 
 
 EX-99.1 2 ex_631554.htm PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED MARCH 8, 2024 ex_631554.htm

Exhibit 99.1

 

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

 

HAYWARD, Calif. [Business Wire] – March 8, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its novel CellFX nsPFA Percutaneous Electrode System for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures.

 

image1.jpg

  

“The FDA clearance of our Percutaneous Electrode System is the initial major milestone for Pulse Biosciences in surgery. It opens a new set of clinical applications and opportunities wherein our proprietary, one of a kind, patented CellFX nsPFA technology is highly differentiated and holds the potential to  change the present time standard of care. I couldn’t be more proud of the engineering, clinical and regulatory teams at Pulse Biosciences for their commitment to bringing the safety and effectiveness benefits of nsPFA to our physician, caretaker and patient partners,” said Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences. “Internally, our team is pleased with its manufacturing and operational readiness as we initiate our training and commercialization programs in the coming weeks. We look forward to providing additional details and color on these commercial programs in our upcoming fourth quarter and full year 2023 earnings conference call scheduled for Thursday, March 28, 2024.”

 

The CellFX nsPFA Percutaneous Electrode System consists of a percutaneous needle electrode for use with the Company’s proprietary CellFX nsPFA Console. The novel electrode is designed to harness and deliver the key advantages of nsPFA energy, enabling precise, nonthermal removal of cellular tissue without damage to noncellular structures or inducing thermal necrosis. This percutaneous electrode is designed for non-cardiac applications.

 

“The CellFX nsPFA Percutaneous Electrode System represents a much needed and promising new minimally invasive nonthermal treatment option for patients. For physicians, the system offers intuitive usability, short procedure times and customizable energy delivery to treat a variety of patients requiring soft tissue ablation,” said Dr. Ralph P. Tufano, the Company’s Senior Advisor and Scientific Advisory Board Chair, Head and Neck Surgery, Clinical Professor of Surgery at the Florida State University College of Medicine and Medical Director, Head and Endocrine Surgery for the Sarasota Memorial Health Care System in Sarasota, Florida. “I am extremely encouraged by the early study results by my colleague, Professor Stefano Spiezia, demonstrating the rapid clearance of ablated cellular tissue and absence of any evidence of thermal damage or residual scarring.”

 

 

About Pulse Biosciences®

 

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

 

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

 

Forward-Looking Statements

 

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s CellFX nsPFA technology and CellFX System to nonthermally clear cells without damaging adjacent noncellular structures or inducing thermal necrosis, statements concerning the Company’s expected product development efforts, such as commercial launch of its CellFX nsPFA Percutaneous Electrode System for soft tissue ablation in percutaneous and intraoperative surgical procedures, statements concerning the Company’s manufacturing and operational readiness to initiate a commercial launch of any product, statements concerning whether any clinical study will show that the Company’s novel nsPFA mechanism of action and percutaneous electrode design will deliver fast and precise soft tissue ablations without evidence of residual scarring, statements concerning market opportunities, customer adoption and future use of the CellFX System to address a range of conditions such as benign thyroid nodules, statements concerning early clinical successes and whether they are predictive of the safety and efficacy of any medical device such as the CellFX nsPFA Percutaneous Electrode System, Pulse Biosciences’ expectations, whether stated or implied, regarding whether the Company’s CellFX nsPFA technology will become a disruptive and durable treatment option for treating any medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

 

Investor Contacts:

 

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

IR@pulsebiosciences.com

 

or
Gilmartin Group
Philip Trip Taylor

415.937.5406
philip@gilmartinir.com

 

 
 EX-101.SCH 3 plse-20240308.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 plse-20240308_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 plse-20240308_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 plse-20240308_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image1.jpg begin 644 image1.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Mar. 08, 2024
Document Information [Line Items]  
Entity, Registrant Name Pulse Biosciences, Inc.
Document, Type 8-K
Document, Period End Date Mar. 08, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37744
Entity, Tax Identification Number 46-5696597
Entity, Address, Address Line One 3957 Point Eden Way
Entity, Address, City or Town Hayward
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94545
City Area Code 510
Local Phone Number 906-4600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol PLSE
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001625101
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.plse.com/20240308/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports plse-20240308.xsd plse-20240308_def.xml plse-20240308_lab.xml plse-20240308_pre.xml plse20240227_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "plse20240227_8k.htm": { "nsprefix": "plse", "nsuri": "http://www.plse.com/20240308", "dts": { "schema": { "local": [ "plse-20240308.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "plse-20240308_def.xml" ] }, "labelLink": { "local": [ "plse-20240308_lab.xml" ] }, "presentationLink": { "local": [ "plse-20240308_pre.xml" ] }, "inline": { "local": [ "plse20240227_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.plse.com/20240308/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "plse20240227_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "plse20240227_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.plse.com/20240308/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001437749-24-007278-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-007278-xbrl.zip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plse20240227_8k_htm.xml IDEA: XBRL DOCUMENT 0001625101 2024-03-08 2024-03-08 false 0001625101 8-K 2024-03-08 Pulse Biosciences, Inc. DE 001-37744 46-5696597 3957 Point Eden Way Hayward CA 94545 510 906-4600 false false false false Common stock PLSE NASDAQ false